google-site-verification: googlec7193c3de77668c9.html

Combination therapy improves progression-free survival for patients with metastatic dMMR colorectal cancer

[
Patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer experienced a 58% reduction in the risk of disease progression or death when treated with atezolizumab (Tecentriq) plus modified FOLFOX6 and bevacizumab (Avastin), compared with atezolizumab alone, according to results from the NRG-GI004/SWOG S1610 COMMIT trial published in the Journal of Clinical Oncology. The combination also produced higher response rates and substantially reduced primary disease progression.


Source link

Advertisements
Views: 1

See also  Does low lipoprotein(a) increase the risk of diabetes? New research suggests it does not

Check Also

ICU design guidelines highlight how hospital environments shape patient care and safety

[ Credit: Zakir Rushanly from Pexels International guidelines developed with contributions from a Texas A&M …

Immune navigation system discovery could lead to better treatments for chronic inflammation

[ A neutrophil, as seen in a peripheral blood smear. Credit: Wikimedia Commons / CC …

Novel AI framework enables efficient collaboration between generalist and specialist models for disease diagnosis

[ Overview of the GSCo framework. Credit: Adapted from Nature Biomedical Engineering (2026). DOI: 10.1038/s41551-026-01653-3 …

Leave a Reply

Available for Amazon Prime
Good tide mango gummies. ← go to elfbar disposable store.